Name: | Lisinopril |
---|---|
PubChem Compound ID: | 5362118 |
Description: | One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. |
Molecular formula: | C21H35N3O7 |
Molecular weight: | 441.519 g/mol |
Synonyms: |
CAS-83915-83-7; Lisinopril; Prinivil (TN); Prinivil; Lisinopril dihydrate; D00362; Prinzide; L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, dihydrate, (S)-; 76547-98-3; 82009-35-6.
show more » |
Name: | Lisinopril |
---|---|
Name (isomeric): | DB00722 |
Drug Type: | small molecule |
Description: | One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. |
Brand: | Acercomp, Inhibril, Sinopril, Prinivil, Noperten, Lisinopril Dihydrate, Lysinopril, Presiten, Zestril, Linopril, Lisipril |
Brand name mixture: | Zestoretic Tab 20/12.5mg(lisinopril + hydrochlorothiazide), Zestoretic Tab 10/12.5mg(lisinopril + hydrochlorothiazide), Lisinopril Comp(lisinopril + hydrochlorothiazide), Zestoretic Tab 20/25mg(lisinopril + hydrochlorothiazide), Prinzide(lisinopril + hydrochlorothiazide) |
Category: | Angiotensin-converting Enzyme Inhibitors, Antihypertensive Agents |
CAS number: | 83915-83-7 |
Indication: | For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or β-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy. |
---|---|
Pharmacology: |
Lisinopril is an orally active ACE inhibitor that antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the ...
show more » |
Mechanism of Action: |
There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, w...
show more » |
Absorption: | Approximately 25%, but widely variable between individuals (6 to 60%) in all doses tested (5-80 mg); absorption is unaffected by food |
Protein binding: | Lisinopril does not appear to be bound to serum proteins other than ACE. |
Biotransformation: | Does not undergo metabolism, excreted unchanged in urine. |
Route of elimination: | Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. |
Half Life: | Effective half life of accumulation following multiple dosing is 12 hours. |
Clearance: | 10 L/h [child weighting 30 kg receiving doses of 0.1 to 0.2 mg/kg] |
Toxicity: | Symptoms of overdose include severe hypotension, electrolyte disturbances, and renal failure. LD50= 2000 mg/kg(orally in rat). Most frequent adverse effects include headache, dizziness, cough, fatigue and diarrhea. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|